Communiqués AbbVie Inc. London S.E.

Actions

0QCV

US00287Y1091

Produits pharmaceutiques

Marché Fermé - London S.E. 17:30:00 28/09/2026			Après clôture 20:27:55
265,00 ^USD	0,00%		266,88	+0,71%

17:51	AbbVie obtient l’autorisation de la FDA américaine pour JUVMO (tavapadon) dans le traitement de la maladie de Parkinson	CI
16:41	Les laboratoires pharmaceutiques américains se tournent vers la Chine pour conclure des accords de licence	RE

Communiqués

14:01	U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease	PR
24/09	EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma	AQ
22/09	AbbVie : Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued	PU
22/09	Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach	PR
22/09	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis	PR
21/09	AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery	PR
18/09	AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026	PR
18/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meeting	AQ
18/09	AbbVie - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	AQ
17/09	AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting	PR
17/09	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	PR
15/09	AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum	AQ
15/09	AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign	PR
15/09	Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit	PR
10/09	AbbVie Declares Quarterly Dividend	PR
10/09	AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine	PR
03/09	AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma	PR
03/09	AbbVie Completes Acquisition of Apogee Therapeutics	PR
03/09	AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	PR
02/09	Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care	PR
01/09	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture	PR
01/09	SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings	PR
31/08	AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference	PR
27/08	AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
21/08	AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline	PR